RxDoctor Payments Data

Amy Stratton

Psychiatric/Mental Health · Grand Rapids, MINPI 1124494539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,376 and has fallen 61.7% since, to $911 in 2024. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,125in general payments, 2019–2025

Across 427 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$914
  • Teva Pharmaceuticals USA, Inc.$755
  • Supernus Pharmaceuticals, Inc.$738
  • Otsuka America Pharmaceutical, Inc.$633
  • Johnson & Johnson$557
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$7,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,125 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$38,426
VraylarCariprazine Hcl11$15,107
TrintellixVortioxetine Hydrobromide14$8,505
Lurasidone Hcl16$3,716
Vilazodone Hcl13$3,375
Duloxetine Hcl38$1,062
Quetiapine Fumarate71$999
Olanzapine39$985
Bupropion XlBupropion Hcl36$975
Lamotrigine73$957
Venlafaxine Hcl ErVenlafaxine Hcl42$955
Trazodone Hcl81$932
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$909
Methylphenidate Hcl39$773
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$557$38,42611 claims
AbbVieVraylar$1,069$15,10711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$409$8,50514 claims
Almatica Pharma LLCSertraline Hcl$71$50337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →